Omeros | OMER - Sales Revenues


Omeros reported $0 in Sales Revenues for its fiscal quarter ending in March of 2022.





Sales Change Date
Adma Biologics USD 134.22M 12.24M Sep/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Cytokinetics USD 17.76M 15.83M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Insmed USD 263.8M 121.8M Dec/2025
Knight Therapeutics CAD 92.26M 3.31M Sep/2024
MacroGenics USD 72.84M 50.6M Sep/2025
Pacira USD 196.87M 17.35M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Rockwell Medical USD 25.83M 3.15M Jun/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xoma USD 25K 5M Sep/2024